Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 89, Issue 2, 2018, Pages 127-137

  Ramanathan, Sudarshini ^a,b,c   Mohammad, Shekeeb ^a,b   Tantsis, Esther ^a,b,d   Nguyen, Tina Kim ^a,b   Merheb, Vera ^a,b   Fung, Victor S C ^c,e   White, Owen Bruce ^f,g   Broadley, Simon ^h,i   Lechner Scott, Jeannette ^j,k   Vucic, Steve ^c,e   Henderson, Andrew P D ^c,e   Barnett, Michael Harry ^e   Reddel, Stephen W ^e   Brilot, Fabienne ^a,b,e   Dale, Russell C ^a,e   Andrews, P ^l   Barton, J ^l   Burrow, J ^l   Butzkueven, H ^l   Cairns, A ^l   Calvert, S ^l   Caruana, P ^l   Chelakkadan, S ^l   Clark, D ^l   Fraser, C ^l   Freeman, J ^l   Gill, D ^l   Grattan Smith, P ^l   Gupta, S ^l   Hardy, T ^l   Kothur, K ^l   Ling, S ^l   Lopez, J ^l   Malone, S ^l   Marriott, M ^l   Nosadini, M ^l   O'grady, G ^l   Orr, C ^l   Ouvrier, R ^l   Parratt, J ^l   Patrick, E ^l   Pilli, D ^l   Riminton, D ^l   Riney, K ^l   Rodriguez Casero, V ^l   Ryan, M ^l   Scheffer, I ^l   Shah, U ^l   Shuey, N ^l   Spooner, C ^l   Subramanian, G ^l   Tea, F ^l   Thomas, T ^l   Thompson, J ^l   Troedson, C ^l   Ware, T ^l   Webster, R ^l   Yiannikas, C ^l   Yiu, E ^l   Zou, A ^l   more..

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d MACQUARIE UNIVERSITY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h GRIFFITH UNIVERSITY   (Australia)

ⁱ GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^j JOHN HUNTER HOSPITAL   (Australia)

^k UNIVERSITY OF NEWCASTLE   (Australia)

^l University of Newcastle ^*

more..

Author keywords

acute disseminated encephalomyelitis; myelin oligodendrocyte glycoprotein antibodies; optic neuritis; outcomes; therapy

Indexed keywords

ANTIBODY; AZATHIOPRINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADOLESCENT; ADULT; AGED; ARTICLE; BILATERAL OPTIC NEURITIS; CHILD; CLINICAL OUTCOME; DEMYELINATION; DISABILITY; DISEASE COURSE; DRUG TREATMENT FAILURE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MYELITIS; OPTIC NEURITIS; PHENOTYPE; RECURRENCE RISK; TREATMENT RESPONSE; UNILATERAL OPTIC NEURITIS; BRAIN; COHORT ANALYSIS; DEMYELINATING DISEASE; DIAGNOSTIC IMAGING; IMMUNOLOGY; INFANT; MIDDLE AGED; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BRAIN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEMYELINATING AUTOIMMUNE DISEASES, CNS; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INFANT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; OPTIC NEURITIS; PREDNISONE; RITUXIMAB; YOUNG ADULT;

EID: 85048284775     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2017-316880     Document Type: Article

References (40)

1. Schluesener HJ, Sobel RA, Linington C, et al. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987;139:4016-21.
2. Brunner C, Lassmann H, Waehneldt T V, et al. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2', 3'-cyclic nucleotide 3'-phosphodiesterase in the cNs of adult rats. J Neurochem 1989;52:296-304.
3. O'connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13:211-7.
4. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with infammatory demyelinating central nervous system disease. Ann Neurol 2009;66:833-42.
5. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71:276-83.
6. Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinfamm 2014;1:e40.
7. Höftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and aQp4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2015;21:866-74.
8. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89.
9. Rostasy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 2012;69:752-6.
10. Dale RC, Tantsis EM, Merheb V, et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinfamm 2014;1:e12.
11. Jarius S, Ruprecht K, Kleiter I, et al. Mog-IgG in NMO and related disorders: a multicenter study of 50 patients. part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinfamm 2016;13:280.
12. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239-45.
13. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fngolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012;18:113-5.
14. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica study Group (NeMOs). J Neurol 2014;261:1-16.
15. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment effcacy. JAMA Neurol 2014;71:324-30.
16. Jeong IH, Park B, Kim SH, et al. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 2016;22:329-39.
17. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol 2016;79:206-16.
18. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and infammatory cNs disease. Neurology 2014;83:142-50.
19. Nosadini M, Alper G, Riney CJ, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinfamm 2016;3:e188.
20. Kurtzke J F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (eDss). Neurology 1983;33:1444-52.
21. Krupp LB, Tardieu M, Amato M P, et al. International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 defnitions. Mult Scler 2013;19:1261-7.
22. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
23. Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 2016;22:470-82.
24. Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015;86:265-72.
25. Dale RC, De sousa C, Chong WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000;123(pt 12):2407-22.
26. Baumann M, Hennes EM, Schanda K, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Mult Scler 2016;22:1821-9.
27. Kremer L, Mealy M, Jacob A, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 2014;20:843-7.
28. Jarius S, Kleiter I, Ruprecht K, et al. Mog-IgG in NMO and related disorders: a multicenter study of 50 patients. part 3: Brainstem involvement-frequency, presentation and outcome. J Neuroinfamm 2016;13:281.
29. Ogawa R, Nakashima I, Takahashi T, et al. Mog antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinfamm 2017;4:e322.
30. Hacohen Y, Mankad K, Chong WK, et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology 2017;89:269-78.
31. Sepúlveda M, Armangue T, Martinez-hernandez E, et al. Clinical spectrum associated with MOG autoimmunity in adults: signifcance of sharing rodent MOG epitopes. J Neurol 2016;263:1349-60.
32. Spadaro M, Gerdes LA, Krumbholz M, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinfamm 2016;3:e257.
33. Jurynczyk M, Tackley G, Kong Y, et al. Brain lesion distribution criteria distinguish Ms from aQp4-antibody NMOsD and MOG-antibody disease. J Neurol Neurosurg Psychiatry 2017;88:132-6.
34. Jurynczyk M, Geraldes R, Probert F, et al. Distinct brain imaging characteristics of autoantibody-mediated cNs conditions and multiple sclerosis. Brain 2017;140:617-27.
35. Kim SH, Kim W, Li X F, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68:1412-20.
36. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 2012;18:1022-6.
37. Montcuquet A, Collongues N, Papeix C, et al. Effectiveness of mycophenolate mofetil as frst-line therapy in aQp4-IgG, MOG-IgG, And seronegative neuromyelitis optica spectrum disorders. Mult Scler 2017;23:1377-84.
38. Sato DK, Callegaro D, Lana-peixoto MA, et al. Distinction between MOG antibody-positive and aQp4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-81.
39. Cobo-calvo Á, sepúlveda M, Bernard-Valnet R, et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications. Mult Scler 2016;22:312-9.
40. Hyun JW, Woodhall MR, Kim SH, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in cNs infammatory diseases. J Neurol Neurosurg Psychiatry 2017;88:811-7.